27.47
-0.38(-1.36%)
Currency In USD
| Previous Close | 27.85 |
| Open | 27.9 |
| Day High | 28.4 |
| Day Low | 27.31 |
| 52-Week High | 70.72 |
| 52-Week Low | 5.21 |
| Volume | 70,116 |
| Average Volume | 113,387 |
| Market Cap | 137.32M |
| PE | -1.97 |
| EPS | -13.95 |
| Moving Average 50 Days | 14.2 |
| Moving Average 200 Days | 10.23 |
| Change | -0.38 |
If you invested $1000 in Mersana Therapeutics, Inc. (MRSN) since IPO date, it would be worth $1,962.14 as of December 05, 2025 at a share price of $27.47. Whereas If you bought $1000 worth of Mersana Therapeutics, Inc. (MRSN) shares 5 years ago, it would be worth $1,152.27 as of December 05, 2025 at a share price of $27.47.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Day One Biopharmaceuticals to Acquire Mersana Therapeutics
GlobeNewswire Inc.
Nov 13, 2025 11:00 AM GMT
Agreement with Day One Biopharmaceuticals provides for upfront consideration of $25.00 per share in cash, plus potential contingent value rights cash payments of up to an aggregate of $30.25 per share, for aggregate deal value of up to approximately
Mersana Therapeutics to Host Third Quarter 2025 Conference Call on November 14, 2025
GlobeNewswire Inc.
Nov 10, 2025 1:00 PM GMT
CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical
Mersana Therapeutics to Host Second Quarter 2025 Conference Call on August 13, 2025
GlobeNewswire Inc.
Aug 06, 2025 12:00 PM GMT
CAMBRIDGE, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical